Congress Materials – Society of Urologic Oncology (SUO 2025)
2025 Society of Urologic Oncology | Dec 2-5 | Phoenix, AZ
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Baseline Urinary Tumor DNA, Minimal Residual Disease and Genomic Disease Burden in Relation to Clinical Response to TAR-200 in the Phase 2b SunRISe-1 Trial
Girish S. Kulkarni, Felix Guerrero-Ramos, Siamak Daneshmand, Andrea Necchi, Giuseppe Simone, Martin Boegemann, Joseph Jacob, Shalaka Hampras, Hussein Sweiti, Abhijit Shukla, Jason Martin, Kate Stromberg, Jiarui Zhang, Karen Urtishak, Jennifer McCann, Patricia Raciti, Shibu Thomas, Flavia Pinho, Joshua Meeks, Michiel S. van der Heijden
This document will be available on December 5th 2025
Comparison of Prostate-Specific Antigen Response Among Metastatic Castration-Sensitive Prostate Cancer Patients Treated With Apalutamide or Abiraterone Acetate – a Real-World Study
Benjamin Lowentritt, Mehmet A. Bilen, Kruti Joshi, Sabree Burbage, Charmi Patel, Frederic Kinkead, Carmine Rossi, Gordon Wong, Dominic Pilon, Neal Shore
Gemcitabine Intravesical System (Gem-iDRS) Monotherapy in Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Characterization of Recurrence, Progression, and Time to Cystectomy
Christopher M. Pieczonka, Siamak Daneshmand, Michiel S. Van der Heijden, Andrea Necchi, Joseph M. Jacob, Felix Guerrero-Ramos, Martin Bögemann, Giuseppe Simone, Nelson Canales Casco, Philipp Spiegelhalder, Evanguelos Xylinas, David Cahn, Yair Lotan, Katie S. Murray, Takashi Kawahara, Karel Decaestecker, Mathieu Roumiguié, Katharine Stromberg, Jason Martin, Abhijit Shukla, Shalaka Hampras, Hussein Sweiti, Daniel Zainfeld
Healthcare Resource Utilization and Medical Costs in Patients With Metastatic Castration Sensitive Prostate Cancer Initiating Apalutamide or Darolutamide in the United States
Daniel Sentana, Ruibin Wang, Sabree Burbage, Cindy Chen, Kruti Joshi, Mehmet A. Bilen
Healthcare Provider (HCP) Experiences with Gemcitabine Intravesical System in Non-Muscle Invasive Bladder Cancer: A Qualitative Study of SunRISe Trial Investigators
Joshua Meeks, Dee Lin, Eliza Raymundo, Thushani Siriwardhane, Timothy Lyon, Lucy Andersen, Claire Kavanagh, Michael Kelleher, Priyanka Madireddi, Kruti Joshi, Meaghan Roach, Richard Murphy, Cory Williams, Alex Filicevas, Petros Grivas
Real-World Assessment of New-Onset Central Nervous System Conditions in Patients With Non-Metastatic Castration-Resistant Prostate Cancer Treated With Apalutamide, Darolutamide, or Enzalutamide
Daniel Sentana Lledo, Charmi Patel, Kruti Joshi, Sabree Burbage, Carmine Rossi, Frederic Kinkead, Gordon Wong, Alessio Palladino, Dominic Pilon, Mehmet A. Bilen
Real-World Clinical Outcomes Among Localized Prostate Cancer Patients With External Beam Radiation Therapy Across Different Risk Stratifications
Gordon Brown, Lawrence Karsh, Charmi Patel, Carmine Rossi, Sabree Burbage, Frederic Kinkead, Francesca Lee, Yuxi Wang, Gordon Wong, Dominic Pilon, Kruti Joshi, Benjamin Lowentritt, Neal Shore
This document will be available on December 5th 2025
Real-World Insights Into the Patient Experience and Gender Disparities During Treatment for High-Risk Non-Muscle Invasive Bladder Cancer
Andrea Kokorovic, Wassim Kassouf, Nimira S. Alimohamed, Peter C. Black, Girish S. Kulkarni, Normand Blais, Aly-Khan A. Lalani, Srikala S. Sridhar, Mia Unsworth, Jacob Skilling, Brendan Osborne, Marie Deault-Bonin, Christopher J.D. Wallis
Real-world Outcomes in Patients with Bacillus Calmette-Guérin (BCG)-unresponsive High-risk Non-muscle Invasive Bladder Cancer with Carcinoma in Situ — A Chart Review Study of the American Urological Association’s Quality Registry
Girish S. Kulkarni, Yi Zhe Wang, Sarah Cote, Dee Lin, Michael Kelleher, Petros Grivas
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
